Targeting KRAS-mutated NSCLC - novel TKIs and beyond.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

KRAS-mutated non-small cell lung cancer (NSCLC) is the most common genetically altered subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated combinations of MEK inhibitors with chemotherapy without success. Here we discuss these studies and novel approaches to targeting KRAS-mutated NSCLC.

Keyphrases

wild type
small cell lung cancer
advanced non small cell lung cancer
brain metastases
cancer therapy
case control
epidermal growth factor receptor
radiation therapy
pi k akt
signaling pathway
atomic force microscopy
tyrosine kinase